These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: [Expression of MAGE-1 gene in hepatocellular carcinoma].
    Author: Cai S, Chen H, Wang Y.
    Journal: Zhonghua Yi Xue Za Zhi; 1999 Sep; 79(9):668-72. PubMed ID: 11715455.
    Abstract:
    OBJECTIVE: To investigate the expression of MAGE-1 mRNA in human hepatocellular carcinoma (HCC) and to discuss the possibility of using MAGE-1 antigens as a new peptide vaccine for immunotherapy for HCC. METHODS: The expression of MAGE-1 mRNA in HCC tissue and the adjacent non-HCC liver tissue was detected using RT-PCR in 45 samples of HCC, 16 samples of cirrhosis and 12 samples of normal liver tissue. The 6 samples of MAGE-1 mRNA positive PCR products were DNA sequenced. The sequenced fragments of MAGE-1 cDNA were used as template to which a [alpha 32P] labeled probe was synthesized and employed for Southern blot analysis. HLA class I-A and I-B typing of 43 HCC patients were assayed by ELISA test. RESULTS: Of the 45 HCC samples, 32 expressed MAGE-1 mRNA. None of the HCC adjacent tissue or liver tissue from cirrhosis or normal liver samples expressed MAGE-1 mRNA. The DNA sequence confirmed that the target gene fragment in all the 6 samples of PCR products was MAGE-1 cDNA. Point mutation occurred in 3 samples resulting in alternation of amino acid residues in 2 positions. Southern blot analysis showed that MAGE-1 was also detectable in HCC tissue which was MAGE-1 positive in RT-PCR assay, but not detectable in non-HCC liver tissue. In HCC patients, the predominant types of HLA were A2(53.5%), A11(25.6%), A24(20.9%), A33(20.9%), B13 (28.3%) and B35(23.2%). MAGE-1 mRNA expression in HCC showed no correlation with the level of alpha-FP in blood and the diameter of tumor. CONCLUSIONS: MAGE-1 mRNA is expressed at a high percentage of HCC samples. This tumor rejection antigen may have potential to be used as a new peptide vaccine for immunotherapy for HCC. There are point mutations of MAGE-1 gene sequence in some Chinese HCC patients.
    [Abstract] [Full Text] [Related] [New Search]